How the LDT Final Rule’s Exemptions Apply to Oncology Labs
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
No company better embodies the vicissitudes of running a COVID-19-focused diagnostics business during the pandemic period than Lucira Health.
HHS secretary takes action to ensure that EUAs remain in effect until the “significant potential” for a COVID-19 PHE no longer exists.
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
While only time will tell how bad the ultimate damage turns out to be, it appears for now at least that the industry has dodged a bullet.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
Agency’s annual report to Congress concludes that providers are doing just fine and don’t need a big bump in pay at this time.
To ensure proper Medicare Part B billing and coding, your billing staff must be aware of all 22 of the newly recognized PLA codes.
Proper usage of ABN-related modifiers is a significant issue that has a direct impact on your lab’s reimbursement and compliance.
In this month’s roundup, three cases—including two whistleblower lawsuits and one workplace discrimination case—get dismissed.
Lab leaders must be able to make a sound assessment of both the costs and benefits, and the liability risks involved.